GlassScriptPhysician profile
Sheikh M Naeem
NPI 1932198538
$4,207.21
in general payments reported to CMS, 2019-2025
36 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $96.99 · 2021: $211 · 2022: $880 · 2023: $918 · 2024: $1,063 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $551.62 | 2019-2025 | |
| Pfizer INC. | $433.45 | 2019-2025 | |
| Amgen INC. | $402.17 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $284.74 | 2022-2024 | Verquvo, Vaxneuvance, Gardasil |
| Gilead Sciences, INC. | $247.39 | 2022-2023 | Vemlidy |
| E.R. Squibb & Sons, L.L.C. | $218.29 | 2019-2024 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $187.18 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.17 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $163.52 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $160.01 | 2019-2022 | |
| Abiomed | $132.79 | 2019 | |
| Baxter Healthcare | $113.49 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Cvrx, INC. | $109.28 | 2024-2025 | Barostim Neo System |
| Boston Scientific Corporation | $108.74 | 2021-2022 | |
| Abbott Laboratories | $87.60 | 2019-2023 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheikh Naeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.